Cite
First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor.
MLA
Gatlik, Ewa, et al. “First‐in‐human Safety, Tolerability, and Pharmacokinetic Results of DFV890, an Oral Low‐molecular‐weight NLRP3 Inhibitor.” CTS: Clinical & Translational Science, vol. 17, no. 5, May 2024, pp. 1–16. EBSCOhost, https://doi.org/10.1111/cts.13789.
APA
Gatlik, E., Mehes, B., Voltz, E., Sommer, U., Tritto, E., Lestini, G., Liu, X., Pal, P., Velinova, M., Denney, W. S., Fu, Y., Opipari, A., Dean, D., & Junge, G. (2024). First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor. CTS: Clinical & Translational Science, 17(5), 1–16. https://doi.org/10.1111/cts.13789
Chicago
Gatlik, Ewa, Beata Mehes, Emilie Voltz, Ulrike Sommer, Elaine Tritto, Giulia Lestini, Xiaoxi Liu, et al. 2024. “First‐in‐human Safety, Tolerability, and Pharmacokinetic Results of DFV890, an Oral Low‐molecular‐weight NLRP3 Inhibitor.” CTS: Clinical & Translational Science 17 (5): 1–16. doi:10.1111/cts.13789.